Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brugge – page 39

1 245 clinical trials in Brugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brugge at a glance
1 245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 245 trials in Brugge

Open in trial search

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nykode Therapeutics ASA

Study on [68Ga]Ga-PentixaFor PET Imaging for Better Risk and Disease Assessment in Patients with Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:University Of Antwerp

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:University College London

Migraine+2

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:CEEGOG z.s.

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Thyroid cancer+1

Recruiting

Study on [18F]PSMA-11 PET Imaging for Patients with Advanced Thyroid and Head and Neck Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide ALF-18
  • Sponsor:Universitair Ziekenhuis Gent

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Rectal cancer

Recruiting

Study of drug combination (capecitabine, fluorouracil, oxaliplatin, calcium folinate) to prevent cancer recurrence in patients with detectable ctDNA after rectal cancer surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:Medical University Of Vienna

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brugge

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Researchers in Brugge are advancing prevention and treatment of bacterial infections and fungal diseases through vaccine and antimicrobial studies.

  • Pneumococcal conjugate vaccine efficacy in infants
  • New antimicrobial agents for resistant bacterial strains
  • Diagnostic tools for invasive fungal infections
  • Safety assessment of novel antifungal prophylaxis

These trials aim to strengthen protection against serious infections and support public health in the region.

02 Cardiovascular Diseases

Investigators are testing innovative therapies to lower heart risk in patients with atherosclerosis, elevated lipoprotein(a), and amyloid‑related cardiomyopathy.

  • GLP‑1 analogue for ASCVD outcomes
  • Lipoprotein(a)‑lowering agent pelacarsen
  • RNA‑based therapy NTLA‑2001 for ATTR cardiomyopathy
  • Muvalaplin to reduce major cardiovascular events

The goal is to reduce morbidity and mortality from heart disease, a leading health concern in Brugge.

03 Digestive System Diseases

Studies target gastrointestinal disorders, evaluating novel compounds for irritable bowel syndrome relief and ulcerative colitis remission.

  • Comparative trial of ebastine vs mebeverine for IBS
  • Obefazimod for endoscopic improvement in ulcerative colitis
  • Long‑term safety of ABX464 in ulcerative colitis
  • Patient‑reported outcomes for bowel symptom management

Advances aim to enhance quality of life for individuals living with chronic digestive conditions.

04 Hemic and Lymphatic Diseases

A range of trials on hematologic malignancies are underway, seeking more effective regimens for lymphomas and acute leukemias.

  • Epcoritamab added to R‑mini‑CHOP for DLBCL
  • Lacutamab combined with GemOx in peripheral T‑cell lymphoma
  • Ziftomenib plus standard chemotherapy for NPM1‑mutated AML
  • Targeted therapy for KMT2A‑rearranged AML

These efforts aim to improve survival and reduce treatment toxicity for patients with blood cancers in the city.

05 Immune System Diseases

Research includes autoimmune and immune‑mediated conditions, testing agents that restore immune balance such as in chronic graft‑versus‑host disease and Graves’ disease.

  • Belumosudil versus best available therapy for chronic GVHD
  • IMVT‑1402 for maintaining euthyroidism in Graves’ disease
  • Immunogenicity study of PCV21 versus 15vPCV in infants
  • Novel immunomodulators for rare immune disorders

Outcomes may provide new options for patients whose immune systems attack their own tissues.

06 Male Urogenital Diseases

Trials focus on advanced prostate cancer, comparing targeted agents with standard chemotherapy to extend survival in metastatic castration‑resistant prostate cancer.

  • BNT324 versus docetaxel in mCRPC
  • Pasritamig combined with best supportive care for late‑line mCRPC
  • Biomarker‑driven therapy for hormone‑refractory prostate tumors
  • Quality‑of‑life assessments in prostate cancer treatment

The aim is to offer men in Brugge more effective therapeutic choices when disease progresses.

07 Neoplasms

Broad oncology programs explore innovative treatments for ovarian cancer and other gynecologic malignancies, including fallopian tube and peritoneal tumors.

  • Sofetabart Mipitecan with/without bevacizumab for platinum‑resistant ovarian cancer
  • Combination strategies for platinum‑sensitive ovarian disease
  • Targeted maintenance therapies after surgery
  • Translational studies linking tumor genetics to response

These studies strive to improve response rates and long‑term outcomes for women affected by gynecologic malignancies in Brugge.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.